RYTM
RHYTHM PHARMACEUTICALS, INC.
NASDAQ · Healthcare · Biotechnology · US
$97.71
−1.32%Sep 10, 2026, 12:00 UTC
Rhythm Pharmaceuticals announced that it and its collaborators will present three posters and three oral presentations on setmelanotide in rare MC4R pathway diseases at the 64th Annual European Society for Paediatric Endocrinology Meeting in Marseille, France, September 8-10, 2026.
Source:Aug 17, 2026, 12:00 UTC
Rhythm Pharmaceuticals appointed Manher (AJ) Joshi as Chief Medical Officer, effective August 17, 2026.
Source:Aug 4, 2026, 12:30 UTC
Rhythm Pharmaceuticals announced preliminary data from an ongoing mid-stage study showing its experimental weekly injectable drug reduced body weight in patients with a rare form of obesity caused by brain damage.
Source:Aug 4, 2026, 11:01 UTC
Rhythm Pharmaceuticals reported second quarter 2026 net product revenue of $71.3 million from global sales of IMCIVREE.
Aug 4, 2026, 11:01 UTC
Rhythm Pharmaceuticals reported a strong U.S. launch of IMCIVREE for acquired hypothalamic obesity, with over 400 patient start forms received since FDA approval as of June 30, 2026.
Source:Jun 15, 2026, 16:51 UTC
Rhythm Pharmaceuticals reported preliminary results from an ongoing Phase 2 study evaluating setmelanotide in patients with Prader-Willi syndrome.
Source: